Podcasts about Pharma

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the weight loss wars, and the other pharma stocks moving on potential M&A action.Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The traditional path to patients is being rewritten. As affordability pressures rise and patient expectations shift, life sciences companies are rethinking the middle — moving beyond payers, providers, and pharmacies to create direct, digital pathways that meet patients where they are.In this episode, host Adrea Cope is joined by Colleen Ferlotti and Rupa Mehta to unpack the rapid rise of Direct-to-Patient (DTP) models: what's fueling the shift, how leaders are navigating regulatory and operational complexity, and why success depends on designing with both discipline and empathy.To learn more about how we can help your team navigate these changing landscapes, please reach out to Mike.Zapiec@vynamic.com Podcast Tags: healthcare, life sciences, life sciences marketing, direct to patient, patient centricity, digital health  Source Links: Triangle Insights Group (August 2025). The Direct-to-Patient Channel in Pharma: A Practical Guide to Protect GTN, Expand Access, and Improve Patient Experience. Panel – Adrea Cope, Colleen Ferlotti, Rupa Mehta Research & Production – Adrea Cope, Colleen Ferlotti, Rupa Mehta, Peter Svalbe, Mike Zapiec Recording & Editing – Mike Liberto For additional discussion, please contact us at TrendingHealth.com.  

Kailera Therapeutics raised $600 million in a recent funding round for two new drugs to manage obesity.

The 2025 MM+M Media Summit is back!As such, our focus for this week's episode is the state of health media.To help us navigate an industry in flux, at a crossroads, under a microscope – whatever your analogy of choice – is Bill Veltre, head of media at Deerfield Group.Leading media operations for a 2025 MM+M Agency 100 honoree, Veltre walks us through the obstacles posed by a growing amount of regulatory changes as well as the evolving role of AI in the industry.For the Trends segment, we discuss the lawsuit filed by Texas Attorney General Ken Paxton against Kenvue over claims it “deceptively” marketed Tylenol. Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

"It costs about $2.5 billion to bring a drug to the market, and only about 30% of those actually succeed or meet their commercial goals when they get to the market."Manufacturing leaders typically focus on the technical challenges directly in front of them—process validation, tech transfer timelines, capacity utilization. But understanding the commercial landscape offers critical intelligence for strategic planning: which therapeutic areas will drive demand, what modalities require capacity investment, and how market access pressures reshape make-versus-buy decisions.Ryan Quigley, CEO of Inizio—a $1.6 billion commercialization services company working with over 700 pharma and biotech clients—offers a window into the commercial trends that ultimately determine manufacturing requirements. His perspective spans both sponsor and service provider roles, including experience at Abbott, AbbVie, and UDG Healthcare.In this PharmaSource podcast episode, Ryan shares his perspective on pipeline composition, which therapeutic areas will drive the most growth, how regulatory and pricing pressures are reshaping strategic decisions, and why flexibility has become the industry's most valuable currency.Read more

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to unveil a new strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the company's investigational doxorubicin-containing dissolvable microneedle array therapy for basal cell carcinoma. The initiative focuses on patients with Gorlin Syndrome—also known as nevoid basal cell carcinoma syndrome—a rare genetic condition that affects an estimated 1 in 31,000 people worldwide. Individuals diagnosed with the disorder can develop hundreds or even thousands of BCCs throughout their lives, often beginning in childhood. Current treatment approaches frequently involve repeated surgeries and ongoing dermatologic interventions, resulting in significant physical scarring, emotional strain, and financial burden. Dr. Bokhari explained that the partnership with the GSA is designed to jointly pursue an Expanded Access IND Program with the U.S. Food and Drug Administration (FDA). This pathway would enable eligible Gorlin Syndrome patients with multiple, recurrent, or inoperable basal cell carcinomas to obtain supervised treatment with SKINJECT™ outside of traditional clinical trials. In addition to facilitating treatment for those with pressing unmet medical needs, the program will support the collection of real-world safety and tolerability data, which will contribute to future regulatory submissions. It will also enable greater incorporation of patient-centered insights into clinical development and long-term treatment strategies. Medicus Pharma is currently underway with its Phase 2 clinical study, SKNJCT-003, which began enrolling patients in August 2024 across nine U.S. trial sites. The study is a double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating SKINJECT™ as a non-invasive therapeutic option for skin-based BCC using proprietary dissolvable D-MNA . Dr. Bokhari emphasized that the collaboration with the GSA reflects Medicus Pharma's mission to bring innovative, patient-friendly cancer treatments to those most in need, while advancing SKINJECT™ toward broader clinical and commercial milestones. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

PODCAST LAS NOTICIAS CON CALLE DE 29 DE OCTUBRE DE 2025 - Advierten a JGO contra pagar los cupones, tienen los juegos del hambre - Cuarto Poder JGo descarta usar fondo de emergencias para los cupones - Cuarto Poder Rumores de big Pharma invertirá en PR, mientras Lilly anuncia partnership con Nvidia - CNBC Federales arrestan por corrupción en Hacienda - El Nuevo Día Harán 27 salones de seguridad para desastres en PR - El Nuevo Día No confirman designada comisionada de seguros - El Nuevo Día Pablo José recomienda unirse a demanda contra Trump para que pague los cupones - Cuarto Poder AEE dice que LUMA quiere que le pase dinero que LUMA no cobra - El Vocero Gobernadora dice que vetaría medida de Impuesto de Inventario si no encuentran  - El Vocero Buscan reducir ganancias de capital a los locales como al os de fuera, pero entonces dicen que esto es darle incentivos a los ricos de fuera y a los de aquí - El Vocero 70 mil contadores no se han arreglado y son estimados - El Vocero AEE tiene déficit de 600 millones - El Vocero Difícil para ICE conseguir empleados fit para trabajar allí a pesar de montones de solicitudes - Axios JGo no se solidariza con DACO ni opina de demanda contra LUMA por enseres - El Vocero Supuestamente hay tres empresas interesadas en venir a trabajar para sustituir a LUMA - El Vocero Más vistas y se atrasa el proceso de Antonieshka por asesinato de Gabriela Nicole - Cuarto Poder Destrucción de Jamaica y ahora entró a Cuba categoría 3 - NWSLogran acuerdo comercial Trump y Corea del Sur, mañana se reúne con Xi el presidente Trump - CNNVan de PR a Jamaica con ayuda médica - Primera Hora Advierten grid energético de USA está bien atrás y hay que meterle turbo para manufactura - Axios Siempre innovando y con los mejores beneficios, MCS PersonalDirecto te ofrece cubiertas accesibles para que cuides de tu salud y la de los tuyos.Con una amplia red de proveedores de más de 15,000 médicos de libre selección.Reembolso de hasta $40 mensuales por membresía a un gimnasio o por un entrenadorpersonal debidamente certificado. Asistencia en el hogar para servicios de cerrajería,plomería y electricidad de hasta $350 por evento hasta 4 veces al año.¡Únete HOY a la gran familia de MCS!¡Salud que completa tu vida! Llama al 787.945.1259 y oriéntate.Endoso pagadoIncluyendo auspicio 

Do you ever feel like you're doing “all the right things” but not seeing real results?In this episode, Greg & Rachel Denning challenge the sacred cows of school, pharma, and religion—not to burn it all down, but to help you keep what serves your family and release what doesn't. You'll learn how to shift from transactional box-checking to transformational growth, so your kids develop inner authority, critical thinking, and personal responsibility.Big idea: You can honor helpful traditions and raise kids who can question wisely, choose higher standards, and own their outcomes—in education, health, spirituality, and life.What we cover:• Why outsourcing your child's education, spirituality, or health stalls growth• How to “keep the good” in institutions while ditching deadweight rules• The path from conformity to character—raising autodidacts who learn for life• Practical habits that create palpable progress in mind, body, spirit, and family cultureKey Takeaways✅ Transactional → Transformational: Results > routines.✅ Inner Authority: Teach kids to think, not just comply.✅ Keep & Elevate: Honor useful rules; raise the standard at home.✅ Autodidact Mindset: Light the fire, don't fill the bucket.✅ Measure Progress: If outcomes don't improve, change the method.Chapters00:00 Challenging Sacred Cows02:32 The Importance of Questioning Traditions04:58 Individual Authority and Personal Growth07:22 Outsourcing Education and Spirituality10:29 Transformational vs. Transactional Experiences13:05 The Role of Institutions in Personal Development15:25 The Quest for Holistic Progress18:27 Facing Fears and Embracing Truth21:28 The Labyrinth of Personal Growth28:40 Facing Fears and Doubts29:32 The Nature of True Education30:51 The Challenge of Conformity32:22 Resisting Authority Thoughtfully33:41 The Importance of Imagination35:03 Faith at the Edge of the Abyss36:18 Questioning Conventional Wisdom38:01 Learning from Others' Experiences40:41 Walking the Labyrinth of Faith41:48 Understanding Meta Truths44:10 The Concept of the Fringe46:44 Navigating the Lower and Upper Fringe49:03 Living Beyond Conformity50:31 Transformational Living Beyond the BasicsMemorable Quotes

When Procter & Gamble asked Atsushi Kitamura to move from finance analysis into running a manufacturing plant, he didn't hesitate. “They always give me next challenge to stretch me,” he tells us. Managing one of P&G's large diaper plants in Japan forced him to apply finance in real-time operations—a proving ground that shaped his comfort with change and appetite for transformation.That readiness carried him from consumer goods to logistics, restaurants, and electronics before arriving at Astellas Pharma, where the stakes are now measured in science and strategy. When he joined in 2023, Astellas had just completed a $6 billion acquisition that shifted it from a net-cash to a net-debt position. Hired to “put financial disciplines and make the balance sheet stronger,” Kitamura tells us he views the moment as a “transformative timing” for the company. Loss of exclusivity on a prostate-cancer drug representing “more than 40 percent of our revenues” demands reinvention.His three-part playbook focuses on growing core brands, investing in science creation, and executing what he calls “sustainable margin transformations.” The approach has begun to pay off—“top line 19 percent, profit 40 percent,” he tells us—signaling a finance organization in renewal.Now he's turning to technology to sustain that momentum. Describing the shift from RPA to “agentic AI,” Kitamura explains, “I just ask agent AI to do that booking.” He calls it a tipping point that will “change significantly the way how we work.”Still, he adds, leadership begins with listening. “Don't pretend I know everything,” he tells us. For Kitamura, finance transformation starts not with machines or metrics—but with humility.

David Murphy, Economics and Public Affairs Editor speaks to Wilbur Ross, former US Commerce Secretary, about the future of the Irish pharmaceutical industry.

- Improvements in Sensor Dot News and AI Engine (0:10) - Demonstration of AI-Generated News Content (3:16) - Development and Impact of Brighteon.ai (6:55) - Introduction of Grokipedia and Naturalpedia (9:46) - Challenges and Future Plans for AI Projects (14:03) - Launch of Vaccine Forensics Website (24:24) - Features and Capabilities of Vaccine Forensics (31:36) - Importance of Independent Media and AI Engines (44:25) - Special Reports on UBI and Food Riots (57:35) - Food Stamp Program and Its Impact on Society (1:20:38) - Political Benefits and Potential Violence (1:25:05) - Economic and Social Consequences (1:33:51) - Preparation and Safety Measures (1:38:28) For more updates, visit: http://www.brighteon.com/channel/hrreport NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Adam Rogers, CEO of NervGen Pharma, highlights the significant unmet medical need for treating spinal cord injuries (SCI), as there are currently no approved pharmacological treatments to promote repair. The science behind this neurotrauma company's drug is designed to interfere with the inhibitory molecules that prevent neurons from regenerating after injury, allowing the nervous system to repair itself. Recent trials have shown success in patients with chronic SCI, indicating that it is possible to promote recovery long after initial damage occurs.. Adam explains, "Our mission at NervGen is to improve the lives of individuals with spinal cord injury. And there are roughly 310,000 individuals with spinal cord injury in the United States, and about 18,000, roughly 18,500 new cases per year. And it's such a difficult injury to treat because, other than largely exercise and physical therapy, there are absolutely no approved pharmacologic treatments that promote functional repair for individuals who have suffered a spinal cord injury." "I'm a physician by training. I practiced for nearly 20 years, and in the medical world, we have always been taught that when a neuron is damaged, as occurs in spinal cord injury, the neuron becomes dystrophic and cannot regenerate. So the medical community has always believed, and I was taught this and even in my practice, that once you have a damaged neuron, that neuron is dead. The problem that we have to solve here is really twofold. Number one, are neurons still viable after a central nervous system (CNS) injury? And number two, if the neuron is viable, how can we get that neuron to sprout, remyelinate, and regrow so that we can gain some function in the end organ that that neuron is supposed to innervate? NervGen's scientific founder, the late Dr. Jerry Silver, dedicated his entire career to understanding what prevented the central nervous system from repairing itself." #NervGenPharma #SpinalCordInjury #RegenerativeMedicine #NeuroTrauma nervgen.com Download the transcript here

Dr. Adam Rogers, CEO of NervGen Pharma, highlights the significant unmet medical need for treating spinal cord injuries (SCI), as there are currently no approved pharmacological treatments to promote repair. The science behind this neurotrauma company's drug is designed to interfere with the inhibitory molecules that prevent neurons from regenerating after injury, allowing the nervous system to repair itself. Recent trials have shown success in patients with chronic SCI, indicating that it is possible to promote recovery long after initial damage occurs.. Adam explains, "Our mission at NervGen is to improve the lives of individuals with spinal cord injury. And there are roughly 310,000 individuals with spinal cord injury in the United States, and about 18,000, roughly 18,500 new cases per year. And it's such a difficult injury to treat because, other than largely exercise and physical therapy, there are absolutely no approved pharmacologic treatments that promote functional repair for individuals who have suffered a spinal cord injury." "I'm a physician by training. I practiced for nearly 20 years, and in the medical world, we have always been taught that when a neuron is damaged, as occurs in spinal cord injury, the neuron becomes dystrophic and cannot regenerate. So the medical community has always believed, and I was taught this and even in my practice, that once you have a damaged neuron, that neuron is dead. The problem that we have to solve here is really twofold. Number one, are neurons still viable after a central nervous system (CNS) injury? And number two, if the neuron is viable, how can we get that neuron to sprout, remyelinate, and regrow so that we can gain some function in the end organ that that neuron is supposed to innervate? NervGen's scientific founder, the late Dr. Jerry Silver, dedicated his entire career to understanding what prevented the central nervous system from repairing itself." #NervGenPharma #SpinalCordInjury #RegenerativeMedicine #NeuroTrauma nervgen.com Listen to the podcast here

It's time to build your family's future on a foundation of true health and freedom. Join us at Future Foundations—because your future generations deserve the best start to the mission that will outlive us… Check it out here. Use code FREEDOM25 for 25% off! Whether you're looking for tinctures, topicals or teas or a deeper connection to your INNATE healing capacity, Noble Task Homestead is here to serve you. Join the movement. Visit NobleTaskHomestead.com/noblestan today and enjoy a 10% discount on your order. San Diego area residents, take advantage of our special New Patient offer exclusively for podcast listeners here. We can't wait to experience miracles with you! Welcome to another powerful episode of the Future Generations Podcast! Host Dr. Stanton Hom sits down with Mark Groves, a human connection specialist with a fascinating journey from pharmaceutical sales to relationship expert and social commentator. This episode is a must-watch for individuals struggling with personal relationships, healthcare professionals seeking deeper insights into emotional health, people interested in understanding social manipulation, those experiencing technology-induced stress, and anyone seeking personal growth and self-awareness. Delving deep into personal healing, societal manipulation, emotional intelligence, and the complex landscape of human behavior during challenging times, this conversation offers transformative insights for viewers looking to understand the intricate dynamics of human connection in our modern world. Highlights: "I was really good at talking about everything but my feelings." "I found myself more connected to myself than ever, even though I was single." "So much of inflammation was caused by emotional dysregulation and trauma." "I felt like I was living in an upside-down world." "Stating the facts of informed consent is considered an attack." Timestamps: 00:01 - Podcast Introduction and Guest Welcome 00:57 - Mark's Journey from Pharmaceutical Sales to Human Connection Specialist 03:58 - Insights into COVID-19 Pandemic Narratives 12:07 - The Psychological Impact of Technology and Social Media 22:49 - Attention as Currency in Digital Platforms 26:47 - Exploring Solutions for Personal Healing and Connection 29:37 - Building Community and Breaking Down Social Divisions 36:27 - Practical Strategies for Technology Detox 45:13 - The Importance of Personal Values and Self-Alignment 53:29 - The Power of Personal Responsibility and Transformation Resources: Remember to Rate, Review, and Subscribe on iTunes and Follow us on Spotify! Learn more about Dr. Stanton Hom on: Instagram: https://www.instagram.com/drstantonhom Website: https://futuregenerationssd.com/ Podcast Website: https://thefuturegen.com Twitter: https://twitter.com/drstantonhom LinkedIn: https://www.linkedin.com/in/stanhomdc Stay Connected with the Future Generations Podcast: Instagram: https://www.instagram.com/futuregenpodcast Facebook: https://www.facebook.com/futuregenpodcast/ Links: https://www.thehivemethod.co/ https://www.instagram.com/thehivemethod.co About: Human Connection Specialist, Speaker, Author, Coach, Podcast Host and founder of Create The Love. Born with an innate curiosity and a hunger for truth, Mark's journey of self-discovery and personal liberation has led him to spend the last decade coaching and inspiring millions worldwide to create the life and love they desire. Through his candid but compassionate, no-BS guidance, Mark has helped empower countless individuals, teams, and companies to step into their most authentic, effective, and loving selves, transform how they relate to themselves and others, and create profound changes in their lives and relationships. The desire to go off grid and have the ability to grow your own food has never been stronger than before. No matter the size of your property, Food Forest Abundance can help you design a regenerative layout that utilizes your resources in the most synergistic and sustainable manner. If you are interested in breaking free from the system, please visit www.foodforestabundance.com and use code "thefuturegen" to receive a discount on their incredible services. Show your eyes some love with a pair of daylight or sunset (or both!) blue-light blocking glasses from Ra Optics. They have graciously offered Future Generations podcast listeners 10% off any purchase. Use code FGPOD or click here to access this discount, and let us know how your glasses are treating you! One of the single best companies whose clean products have supported the optimal wellness of our family is Earthley Wellness. Long before there was a 2020, Kate Tetje and her team have stood for TRUTH, HEALTH and FREEDOM in ways that paved the way for so many of us. In collaboration with this incredible team, we are proud to offer you 10% off of your first purchase by shopping here. Are you concerned about food supply insecurity? Our family has rigorously sourced our foods for over a decade and one of our favorite sources is Farm Match and specifically for San Diego locals, "Real Food Club PMA". My kids are literally made from their maple breakfast sausage and the amazing carnitas we make from their pasture raised pork. We are thrilled to share 10% off your first order when you shop at this link. Another important way to bolster food security is by supporting local ranchers. Our favorite local regenerative ranch is Perennial Pastures. They have the best nutrient-dense meats that are 100% grass-fed and pasture-raised. You can get $10 off of your first purchase when you use the code: "FUTUREGENERATIONS" at checkout. Start shopping here.

In this episode, we explore how the consumerization of healthcare has pharma thinking more like retailers. RVO Health's Suzy Jackson joins us to talk about its new digital health division and what “direct-to-patient” really means for the patient experience. Plus, who's driving this shift inside pharma, and the one piece of advice every brand should take into 2026. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here. Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tregua Usa-Cina sui dazi; Mercati, ottobre in verde ma Goldman Sachs mette in guardia; Test conti per i Magnifici 7; La settimana delle banche centrali; Pharma, Novartis fa shopping. Puntata a cura di Elisa Piazza - Class CNBC Learn more about your ad choices. Visit megaphone.fm/adchoices

Dans ce numéro du Journal des biotechs, l'analyste biotech Frédéric Gomez revient sur les progressions boursières du moment avec Medincell (/cours/1rPMEDCL/)et Nanobiotix (/cours/1rPNANO/). Il analyse également la situation de Novo Nordisk et livre son coup de cœur sur Genmab.L'entretien est consacré à THX Pharma. Son PDG Mathieu Charvériat revient sur les derniers développements en cous de la biotech. Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

This is a free preview of a paid episode. To hear more, visit andrewsullivan.substack.comKaren is a tech journalist and leads the Pulitzer Center's AI Spotlight Series — a program that trains journalists on how to cover AI. She was a senior editor for AI at MIT Technology Review and a reporter for the WSJ covering Chinese and US tech companies. Her first book is Empire of AI: Dreams and Nightmares in Sam Altman's OpenAI — the most accessible and readable narrative of the rise of AI.For two clips of our convo — on the environmental impact of AI, and its threats to democracy — head to our YouTube page.Other topics: raised by two computer scientists; her mechanical engineering at MIT; the birth of AI at Dartmouth; IBM Watson on Jeopardy!; how the internet made data cheap to collect; the junk info swept into AI; massive data centers; ideology driving the AI industry more than science; ChatGPT; the networking and fundraising skills of Sam Altman; his family scandal; his near ouster at OpenAI; the AI bubble and propping up 401(k)s; the threat to white-collar jobs; the brutal conditions of AI work in developing countries; Chinese authoritarianism and DeepSeek; the illiberalizing effect of Silicon Valley; Musk and Thiel; how the IDF uses AI against Hamas; autonomous weapons; how AI has done wonders with Pharma; transhumanism; chatbot safety for kids; Pope Leo's tech warnings; and AI as the ultimate apple in the Garden of Eden.Browse the Dishcast archive for an episode you might enjoy. Coming up: David Ignatius on the Trump effect globally, Mark Halperin on the domestic front, Michel Paradis on Eisenhower, Fiona Hill on Putin's war, and Arthur Brooks on the science of happiness. As always, please send any guest recs, dissents, and other comments to dish@andrewsullivan.com.

In today's episode on 24th October 2025, we tell you why the world's pharmacy still needs China's chemistry and what India can do to catch up.

Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broader industry trends where companies reassess their operational strategies for greater efficiency. While this decision may impact the local workforce and supply chain dynamics, it underscores a wider reevaluation within the industry regarding sourcing strategies and optimizing production capabilities.Turning to regulatory news, Amgen and AstraZeneca have achieved a notable milestone with Tezspire, which has received approval for a second indication in both the U.S. and Europe. This success highlights the strategic importance of expanding drug indications to maximize therapeutic potential and market reach. The approval also reflects a trend where robust clinical data supports regulatory endorsements across various regions, enhancing the global footprint of pharmaceutical innovations.In manufacturing developments, Galderma is making headlines with a $650 million investment in U.S.-based production facilities for Nemluvio. This commitment to domestic manufacturing aligns with industry-wide movements towards reshoring production to bolster supply chain resilience. As demand for dermatological products increases, enhancing local infrastructure promises not only to meet market needs but also to secure supply stability in uncertain times.Meanwhile, Moderna's recent decision to discontinue its congenital cytomegalovirus vaccine program after disappointing Phase 3 results illustrates the inherent uncertainties present in vaccine development. Despite extensive efforts, the vaccine did not demonstrate sufficient efficacy in preventing CMV infections among women. This outcome serves as a reminder of the critical role that robust clinical trial data plays in guiding strategic decisions within pharmaceutical pipelines. While mRNA technology has seen success against COVID-19, this setback highlights complexities involved when tackling other viral pathogens, potentially redirecting Moderna's focus towards more promising candidates.Roche is navigating through challenges such as currency fluctuations and slower-than-expected pharmaceutical sales in its third quarter. Despite these headwinds, Roche projects confidence in its long-term growth strategies, showcasing resilience through its diversified portfolio. Furthermore, Roche's decision to discontinue five Chugai solid tumor assets reflects broader industry movements towards reassessment and realignment within pipelines. Such decisions often emerge from early-phase trials failing to meet expected outcomes or shifts towards areas with greater promise, enabling companies like Roche to streamline resources towards more viable therapeutic areas.Compliance remains under scrutiny at Nephron Pharmaceuticals as ongoing FDA issues emphasize the necessity of maintaining stringent quality standards throughout manufacturing processes. Such regulatory challenges highlight the criticality of ensuring product safety and efficacy within the industry.On the technological front, the integration of artificial intelligence into life sciences commercialization is transforming industry landscapes. Though many organizations are still catching up with this digital shift, those that have embraced AI are experiencing significant improvements in efficiency and patient engagement. As companies continue embedding AI into their strategic frameworks, these initiatives promise to redefine operational paradigms and open new paths for growth.The landscape remains dynaSupport the show

As Gen Z steps into the healthcare workforce, they're bringing new expectations for authenticity, technology, and purpose-driven brands. The old pharma playbook? Invisible to this generation.In this episode of Trending Health, host Adrea Cope sits down with Carolyn Frantz and Mindy McGrath to explore how life sciences marketers can evolve to engage the next generation of HCPs and patients — from short-form content and streaming-first strategies to redefining the pharma rep of the future.To learn more about how we can help your team navigate these changing landscapes, please reach out to Carolyn.Frantz@vynamic.com or Mike.Zapiec@vynamic.comPodcast Tags: healthcare, life sciences, life sciences marketing, Gen Z, digital health, brand authenticitySource Links:Gen Z more likely to report mental health concernsGeneration X Faces Higher Cancer Rates Than Boomers: StudyPanel – Adrea Cope, Carolyn Frantz, Mindy McGrathResearch & Production – Adrea Cope, Carolyn Frantz, Hannah Yee, Mike ZapiecRecording & Editing – Mike Liberto, Rachel SkoneckiFor additional discussion, please contact us at TrendingHealth.com.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired Avadel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avadel's long-acting narcolepsy drug, Lumryz. This move not only acts as a growth catalyst for Alkermes but also strategically positions the company to potentially advance its own narcolepsy candidate, Alixorexton. This acquisition highlights a broader trend within the industry: a shift towards consolidation and specialization in niche therapeutic areas, reflecting the ongoing strategic maneuvering within the pharmaceutical sector to enhance therapeutic portfolios.In regulatory developments, there is an ongoing discussion around FDA cancer drug policies that's gaining attention. Eli Lilly's Oncology President has highlighted the need for clearer regulatory pathways. The debate revolves around whether to prioritize survival metrics without crossover incentives or encourage U.S. participation through crossover designs. This underscores a tension between maintaining regulatory rigor and offering flexibility in clinical trial design—a balance that impacts how quickly new oncology therapies can reach patients.Turning to international trade, there are significant movements as the Trump administration initiates a probe under Section 301 of the Trade Act of 1974. The aim is to assess if foreign nations are contributing their fair share to drug costs. Such an investigation could lead to tariffs, potentially altering global pharmaceutical trade dynamics and influencing international pricing strategies. Reports suggest that former President Donald Trump is exploring strategies to impose tariffs on U.S. trading partners not adequately compensating for pharmaceuticals, reflecting ongoing tensions regarding international drug pricing.Technology is revolutionizing life sciences commercialization strategies, with AI playing a pivotal role. Despite many organizations not being fully prepared for this digital shift, companies like Real Chemistry are pioneering AI applications to navigate regulatory complexities such as FDA marketing compliance. This digital transformation is set to redefine how pharmaceutical companies engage with patients and healthcare providers, enhancing efficiency and compliance.In legal news, Regeneron has settled a patent dispute with Celltrion over Eylea, allowing for the launch of a biosimilar by the end of 2026. This settlement is part of the growing biosimilars market, which offers cost-effective alternatives to high-priced biologics and enhances patient access to essential therapies.The industry's focus on oncology is further exemplified by Takeda's $1.2 billion upfront payment to Innovent Biologics for cancer assets. This deal includes substantial milestone payments, marking oncology as a key growth area post-Entyvio era and highlighting the high stakes associated with breakthrough cancer therapies. Continuing with significant industry maneuvers, Takeda Pharmaceuticals has announced a potential investment up to $11.4 billion to acquire three antibody-drug conjugates from Innovent Biologics. This deal includes an upfront payment of $1.2 billion and up to $10.2 billion in milestone payments—highlighting Takeda's commitment to expanding its oncology portfolio with innovative therapies that promise enhanced treatment outcomes for cancer patients.Ipsen's acquisition of ImCheck Therapeutics for $1.6 billion further emphasizes this focus on novel cancer treatments. The move includes ImCheck's mid-stage leukemia monoclonal antibody ICT01—an asset aimed at acute myeloid leukemia—indicating Ipsen's strategic push intSupport the show

With the 2025-26 NHL season underway, the Florida Panthers have set out to accomplish a three-peat.Meanwhile, AstraZeneca has another goal in mind.The British pharma giant is continuing with its decades-long Get Body Checked Against Cancer campaign.With the assistance of agency partner Grey Health, AstraZeneca is on an ongoing quest to eradicate the stigma around getting screened for cancer and ignite a passion among fans to take a more proactive approach to their health. During Advertising Week, reporter Heerea Rikhraj moderated a panel with two leaders from Grey Health – chief creative officer Bruno Rebelo and planning director Astrid Kramm – about the latest iteration of the campaign and how effective it has been in terms of boosting cancer screening rates.For this week's podcast, Heerea reconnects with Bruno and Astrid about what else the agency has in the pipeline to support AstraZeneca throughout the season.And for our Trends segment, we're talking about how OpenAI's social media app Sora could disrupt medical marketing.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I get a lot of questions from students and early-career professionals about what different industry roles actually mean: what does a Quality Engineer do? What's Regulatory Affairs? How does R&D fit in?In this video, I walk through eight of the most common roles you'll find in pharma, medtech, biotech, and diagnostics companies. We'll talk about what each team does, how they connect, and how to think about which one might fit your strengths and interests.If you're trying to figure out where you belong in industry, this one's for you.Please like, share, and subscribe if you find it helpful!Timestamps00:00 Introduction and Background01:07 Overview of Industry Roles02:43 Quality Assurance06:14 Regulatory Affairs08:22 Research & Development09:46 Clinical Affairs11:07 Manufacturing & Operations12:09 Quality Control / Analytical Testing14:05 Supply Chain & Procurement15:13 Validation & Technical Services16:39 Career Path Insights and ConclusionSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Gil Roth, President, at Pharma & Biopharma Outsourcing Association (PBOA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering: How planned FDA budget cuts and the ongoing US government shutdown are impacting the industry. And the potential outlook if those issues remain unresolved... Why positive early-phase clinical trial activity could signal a stronger year ahead Real-life applications of AI and machine learning for GMP in CDMOs through signal and pattern recognition Why Gil is feeling more optimism across the CDMO community And yes… you can also see Gil and Raman together on stage at the industry's very own “Super Bowl” of conferences Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference. Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called The Virtual Memories Show (https://chimeraobscura.com/vm).   Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

In this episode of Pharmaceutical Soccer, Clay Trainum and Valair Shabilla discuss Nashville SC's recent performance, including a tough loss to Inter Miami. They reflect on the team's community impact, analyze the game, and preview the upcoming playoffs. The conversation also touches on the complexities of the MLS playoff format, coaching decisions, and the importance of media relations in sports. The hosts share their predictions for Nashville's playoff journey and highlight the significance of developmental leagues in shaping future talent.

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Fatigue? Inflammation? Brain fog? Aging? Pain? Stress? Weakness? https://bit.ly/48tVRyq   Ready to discover what's really holding you back from feeling your best?

In this episode of Denatured, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players — from hospitals and universities to manufacturers and investors — are rethinking their strategies amid global supply chain disruption.The conversation highlights both immediate operational responses and long-term structural shifts shaping a more resilient, agile, and locally grounded ecosystem, especially in light of U.S. tariffs.This episode is presented in partnership with Element Materials Technology.HostsJennifer Smith-Parker, Director of Insights, BioSpaceLori Ellis, Head of Insights, BioSpaceGuestsDr. Jihye Jang-Lee, Director of Technical Services, Element Materials TechnologyDr. Khanh Courtney, Biologics Technical Strategy Manager, Element Materials TechnologyDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

One of the world's most respected pharmaceutical entrepreneurs, Robert "Stan" Loomis is the Founder of Olympia Pharmaceuticals and Wesley Pharmaceuticals. In this download, OBJ Editor-in-Chief Richard Bilbao leads a lively and informative conversation with Loomis, who shares his insight and outlook.

We discussed a few things including:1. Their career journeys2. Merck's venture strategy and GHIF story3. MSD Idea Studios4. CVC landscape and trends5. Outlook for pharma and innovationBill has led MSD Global Health Innovation (GHI) since 2010, playing a strong role in the US company's transition a decade ago from general consumer pharmaceuticals to a focus on biopharmaceuticals and oncology.With 45 portfolio companies and about 80% having commercial agreements with MSD, His approach of always seeking to understand and solve the parent company's core challenges has proven successful.Last year, the fund expanded beyond the US, launching two accelerator programms, one in Berlin covering central Europe and one in Singapore covering 10 Asian countries. The accelerators will also invest at an earlier stage than the growth stage-focused core GHI fund has typically done.Both in the US and abroad, GHI is focused on four key areas of pharma services: drug discovery, clinical development, supply chain and patient access.In drug discovery, Bill is particularly excited about AI and machine learning allowing drugs to be identified faster.  The fund has invested in about 12 companies applying AI to biology, chemistry and vaccines in the past two years, with a belief that these technologies are on the cusp of a breakthrough.Clinical development is another critical focus, especially in patient diversity and trial management.The unit is also exploring supply chain innovations, with systems tracking raw materials coming in and finished goods going out, much like a “control tower at an airport”.A veteran of the venture capital sector, Bill maintains that corporate venture capital is becoming increasingly sophisticated.  He believes corporate venture capital has now established itself as “part of the ecosystem of investing” and offers unique value that traditional investors cannot.----Joel is a seasoned executive with extensive experience in venture investments and strategic innovation within the healthcare sector.  With a career spanning over two decades, he has held pivotal roles at renowned organizations like Merck, J&J, and JPMorgan, focusing on biotech, corp dev and health equity.  He excels in bridging the gap between life sciences and digital health technology.  He is a recognized advocate for diversity and inclusion, emphasizing health equity in his professional endeavors.  #podcast #afewthingspodcast

In this 5 in 5 episode, I breaks down five key lessons from Dominic Colenso, actor turned communication coach, on how to present and connect with impact in Pharma, Life Sciences, and Healthcare.Learn how to start with your audience, tell powerful stories, design smarter slides, and lead with emotion to inspire action.Perfect for professionals who want to communicate clearly, confidently, and persuasively.Watch on YouTube: https://youtu.be/ZKZs7FH1yHIListen on Apple Podcast: https://podcasts.apple.com/gb/podcast/hands-on-business-the-h-files-unlocking-growth/id1548129226

ASX-listed Mayne Pharma saw its shares spike 14% after a court ruled that its acquirer cannot terminate its $672 million acquisition offer Ray-Ban maker EssilorLuxottica just hit record sales as smart glasses go from nerdy to need one now Nestlé’s new CEO is cutting 16,000 jobs as it looks to trim costs while also speeding up growth _ Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.__See omnystudio.com/listener for privacy information.

Join us for another episode in our popular Student Stories series, featuring Dr Frank Douglas, a scholar for whom education was pivotal in his life's journey. From his beginnings in Guyana to his work in global pharma leadership, we'll follow Frank's journey of "bouncing forward": of scholarships and hard work, undertaking a PhD in America, facing racial discrimination in the workplace, and beginning a new career after medical school.Frank also shares his clear methods for turning setbacks into strengths through hard work, perseverance and understanding how to turn your own problems into solutions for everyone.Delving into racial history in America, this episode, released during Black History Month 2025, celebrates Frank's achievements and extraordinary life.**You might also enjoy:Episode 18 of the Exam Study Expert podcast, featuring industry Titan Josaia Mar : https://examstudyexpert.com/coconut-shells-to-industry-titan-when-i-grow-up-month/**Find out more about Dr Frank Douglas:• Discover resources on anti-fragility and perseverance on his website: https://www.safehavendialogues-llc.com/• Listen to his podcast, Reframe for Resilience on your favourite podcast player, or at: https://www.safehavendialogues-llc.com/podcast  **Find out more about Exam Study Expert:Hosted by William Wadsworth, memory psychologist, independent researcher and study skills coach. I help ambitious students to study smarter, not harder, so they can ace their exams with less work and less stress.   • BOOK 1:1 COACHING to supercharge your exam success: https://examstudyexpert.com/workwithme/ • Get a copy of Outsmart Your Exams, my award-winning exam technique book, at https://geni.us/exams *     Podcast edited by Kerri Edinburgh.*As an Amazon Associate, I earn from qualifying purchases on suggested books.Questions? Comments? Requests? Or just want to say "thanks" - send me a text message (I read them all!).

How did the week's AI dealmaking affect stocks? And why did President Trump's comments on weight-loss drugs hurt pharma shares? Plus, how did the big six U.S. banks finish out the week after strong quarterly reports? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

How did the week's AI dealmaking affect stocks? And why did President Trump's comments on weight-loss drugs hurt pharma shares? Plus, how did the big six U.S. banks finish out the week after strong quarterly reports? Host Francesca Fontana discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to another Foiled Friday episode. On this little episode I rant a little bit about Big Pharma and how the government just doesn't actually care about any of us. If you're a fan of Tinfoil Tales, this is just a solo episode with Brandon. Foiled Fridays are just my way of venting some of the things I think about. It could be funny, it could be serious, but it's a little different than a normal Tinfoil Tales episode.Become a supporter of this podcast: https://www.spreaker.com/podcast/tinfoil-tales--6147818/support.Tinfoil Tales Podcast - Show Notes 

Adalvo: Exploring European B2B Pharma's Next Steps by Citeline

Welcome back to the EUCVC Summit Talks, where we bring you candid conversations with Europe's leading founders, corporate leaders, and investors shaping the future of venture collaboration.In this episode, Anne C. Fleischer, Global VP of Consumer Engagement and New Business Models at Novo Nordisk, joins Henrijette Richter, Managing Partner at Sofinnova Partners, for a conversation on the future of health innovation.Together they explore how corporates and VCs are driving the next wave of digital health, the role of AI in transforming patient care, and what it takes to turn breakthrough science into scalable business models.

Pharma meds were never designed to “fix” you. In this video, we'll discuss some of the pharmaceutical industry's secrets, the truth about prescription drugs, and the money-making scheme known as the US healthcare system. Pharma meds were never designed to “fix” you. In this video, we'll discuss some of the pharmaceutical industry's secrets, the truth about prescription drugs, and the money-making scheme known as the US healthcare system. In 1938, the Food, Drug, and Cosmetic Act redefined the word “drug,” giving Big Pharma a monopoly over your body. By this new definition, any natural remedy, such as a plant, herb, or food that helps an ailment in some way, can now be classified as a drug.In 1900, there were fewer than 200 diseases. There are now over 17,000! This has allowed disease to become a huge, profitable business. Drug patents are protected and policed by the FDA. This means you can not sell or profit from a natural remedy, even if it's backed by legitimate research, without FDA approval. Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the Director of Dr. Berg Nutritionals and author of the best-selling book The Healthy Keto Plan. He no longer practices, but focuses on health education through social media.Disclaimer: Dr. Eric Berg received his Doctor of Chiropractic degree from Palmer College of Chiropractic in 1988. His use of “doctor” or “Dr.” in relation to himself solely refers to that degree. Dr. Berg is a licensed chiropractor in Virginia, California, and Louisiana, but he no longer practices chiropractic in any state and does not see patients, so he can focus on educating people as a full-time activity, yet he maintains an active license. This video is for general informational purposes only. It should not be used to self-diagnose, and it is not a substitute for a medical exam, cure, treatment, diagnosis, prescription, or recommendation. It does not create a doctor-patient relationship between Dr. Berg and you. You should not make any change in your health regimen or diet before first consulting a physician and obtaining a medical exam, diagnosis, and recommendation. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A new limited series of the Syneos Health Podcast, Conversations on Commercialization unpacks how biopharma leaders are rewriting the commercial playbook, redefining what it takes to succeed.  Recorded at Fierce Pharma Week 2025, the series continues with part two of our conversation with Mark Bard, co-founder of the Digital Health Coalition. In this episode, Bard and host Tyler Cowan turn the lens to patients, exploring how direct-to-patient models are disrupting traditional care and the implications of reduced physician involvement. They also tackle the rise of agentic AI, what it could enable and what commercial teams should be thinking about now. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at https://www.syneoshealth.com/insights-hub. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Come have a listen of this fantastic interview with Anne Moulin, President of Dome Pharma. Anne and her exceptional team at Domes Pharma are changing the way pharmaceutical companies run in the veterinary space. Her positivity and willingness to risk it all for her family, company, and product is astonishing.Support the show

A monster study comparing vaccinated children to unvaccinated children (four years before Covid) leads to damning results for Pharma, and the researcher who conducted it. Why is there such a culture of silence in science? Alec Baldwin crashes into a tree and blames the tree. Canceled Dilbert cartoonist Scott Adams with his tear-jerking reaction to yesterday's peace deal. How watching the hostages' release confirmed that Adams' cancellation (or ex-communication) for supporting Donald Trump was entirely worth it.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Valair is missing. Clay and Stephen discuss a week where there was no Nashville SC action. They talk about the International break, players that participated in it, local soccer and preview the last game of the regular season against Inter Miami.  As always, thanks for listening!